嵌合抗原受体
医学
单克隆抗体
疾病
靶向治疗
临床试验
淋巴细胞白血病
白血病
免疫学
T细胞
抗体
癌症
免疫系统
内科学
标识
DOI:10.1080/13543784.2023.2161361
摘要
Despite advances in treatment approaches in acute lymphoblastic leukemia (ALL), the prognosis of adults with newly diagnosed T-ALL remains poor, as well as that of adults and children with relapsed disease. Novel targeted therapies are therefore needed.This review summarizes promising emerging strategies for the treatment of T-ALL.The recent molecular characterization of T-ALL has led to the identification of new therapeutic targets. Small-molecules inhibitors and other targeted therapies have therefore been recently developed and are currently under clinical investigations. Similarly, first studies involving monoclonal antibodies and chimeric antigen receptor (CAR) T cells have shown encouraging results. Improvement of outcome with these novel approaches, eventually combined with current standard chemotherapy, is therefore expected in a near future in T-ALL.
科研通智能强力驱动
Strongly Powered by AbleSci AI